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Other names: hsa-mir-21; miR-21 
Location: 17q23.1 
Location base pair: MIRN21 is located on chr17: 
55273409-55273480 (+). 
Local order: Based on Mapviewer, genes flanking 
MIRN21 oriented from centromere to telomere on 
17q23 are:  
- TMEM49, transmembrane protein 49, 17q23.1. 
- MIRN21, microRNA 21, 17q23.1. 
- TUBD1, tubulin, delta 1, 17q23.1. 
- LOC729565, similar to NADH dehydrogenase 
(ubiquinone) 1 beta subcomplex, 8, 19 kDa, 17q23.1. 
- RPS6KB1, ribosomal protein S6 kinase, 7 0kDa, 
polypeptide 1, 17q23.1. 
DNA/RNA 
Description 
The gene is located in an intergenic region. The length 
of MIRN21 gene is reported as 3433 nucleotides long. 
It overlaps with the 3' UTR end of the Transmembrane 
Protein 49 (TMEM 49) (also known as Human Vacuole 
Membrane Protein 1, VMP-1). 
Transcription 
RNA Pol II is suggested to be the most likely enzyme 
involved in miRNA transcription. However, current 
studies also provide evidences for RNA Pol III 
dependent transcription of few miRNAs interspersed 
among repetitive Alu elements. 
For MIRN21, the major RNA polymerase is likely to 
be RNA Pol II due to the presence of 5' cap and 3' poly
(A) tail of the pri-MIRN21. Chromatin 
immunoprecipitation (ChIP) analysis of upstream  
 
sequences of MIRN21 showed enrichment for Pol II 
but not Pol III. 
MIRN21 gene was shown to harbor a 5' promoter 
element. 1008 bp DNA fragment for MIRN21 gene 
was cloned (-959 to +49 relative to T1 transcription 
site, see Figure 1; A). Analysis of the sequence showed 
a candidate 'CCAAT' box transcription control element 
located approximately about 200 nt upstream of the T1 
site. T1 transcription site was found to be located in a 
sequence similar to 'TATA' box 
(ATAAACCAAGGCTCTTACCATAGCTG). To test 
the activity of the element, about 1kb DNA fragment 
was inserted into the 5' end of firefly luciferase 
indicator gene and transfected into 293T cells. The 
sense orientation insert, unlike antisense, induced 
luciferase activity. 
pri-MIRN21 gene was reported to have two 
transcription sites, T1 and T2. T1 (identified by RACE, 
+1 start site) was reported as the minor transcription 
site and T2 (identified by RACE, +27 start site) as the 
major transcription start site. Based on the data of 
pmiR-21-luc expression plasmid, the endogenous pri-
MIRN21 was suggested to utilize T1 and T2 sites for 
initiation of transcription (Figure 1; A). 
The maturation of miRNA gene involves sequential 
process. 
Pri-miRNA  
The miRNA genes are first transcribed in nucleus as 
long primary transcripts called pri-miRNA. The 
primary transcript for MIRN21 is found to be 3433-nt 
long. 
For localization of the pri-MIRN21 transcript, total, 
nuclear and cytoplasmic RNA fractions from HeLa 
cells were oligo-dT primed and reverse transcribed into 
cDNA. pri-MIRN21 transcript was found mainly in the 
nucleus as well as modest levels in the cytoplasm. 
Sequence: NCBI cDNA clone: BC053563. Length: 
3389bp 
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Figure 1. A: Characterization of the full-length about 3433 nt pri-MIRN21. 
Open Reading frame analysis within the 3433 nucleotides identified a potential 124 amino acids long peptide. This uncharacterized ORF 
is located near the transcription start site (+114). 
This potential peptide sequence shows homology to a 180-amino-acid human protein. However, it is not clear yet if pri-MIRN21 functions 
as an mRNA as well. 
Figure 1. B: Stem-loop structure of MIRN21. 
 
Pre-miRNA  
The primary transcripts of microRNAs are processed 
by enzymatic microprocessor Drosha (RNase III 
enzyme) and DGCR8 (dsRNA binding protein) from 
their 3' and 5' cleavage sites into an intermediate stem-
loop precursor or pre-miRNA in the nucleus. 
The precursor of MIRN21 is 72 bases long (pre-
MIRN21), forms a secondary structure, and contains 
the mature miRNA sequence, stem and terminal loop 
structures with 2-nt 3'overhang (Figure 1; B). The 
precursor is then transferred from nucleus to cytoplasm 
by the enzyme Exportin 5. In cytoplasm, a second 
RNase III enzyme, Dicer, removes terminal loop 
generating about 20-bp RNA duplex. 




CUGUCUGACA (Figure 1; B). 
Mature MIRN21  
The mature miRNA forms one strand of the RNA 
duplex. One strand is degraded and other is  
incorporated in to a protein complex, RNA induced 
silencing complex (RISC), targeting a partially 
complementary target mRNA. 
MIRN21 is 22 nucleotides long. 
Sequence: UAGCUUAUCAGACUGAUGUUGA. 
Pseudogene 
No reported pseudogenes. 
Protein 
Note: miRNAs are not translated into amino acids. 
Mutations 
Note: In a panel of 91 human cancer cell lines 
representing several human cancers, sequencing 
showed no sequence variations in mature miRNAs. 
In HCT-15 colon cancer cell line, pri-MIRN21 showed 
a A+29G (A/G) heterozygous variation (Figure 2). 
It was suggested that sequence variations in pri-
miRNAs may cause structural alterations. However, the 
variation was not found to be affecting pri-MIRN21 
processing when it was compared to the wild type. 
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Note: Overexpression was fist shown in glioblastoma 
and then in papillary thyroid carcinoma (PTC), breast 
tumors and other various tumors (e.g. colorectal 
carcinoma, lung tumors, pancreatic tumors, prostate 
tumors, stomach tumors cholangiocarcinomas, 
neuroblastoma, hepatocellular carcinoma and uterine 
leiomyomas) and cervical adenocarcinoma cell line, 
HeLa. 
Relatively low expression was seen in cell lines HL-60 
(promyelocytic leukemia), K562 (chronic myelogenous 
leukemia) and prostatic adenocarcinoma cell line. 
miRNA microarray data from 540 samples from 6 solid 
cancers (lung, stomach, prostate, colon, pancreatic and 
breast) showed overexpression of MIRN21 gene 
compared to normal cells. 
Glioblastoma 
Disease 
Overexpression of MIRN21 was first shown in 
malignant human brain tumor cells. When, human 
glioblastoma tumor tissues, 12 early passage cultures 
(passage 3) from high grade gliomas and 6 
glioblastoma cell lines (A172, U87, U373, LN229, 
LN428 and LN308) were compared to non-neoplastic 
glial cells and a variety of mammalian tissues, MIRN21 
was found to be strongly overexpressed in the 
neoplastic samples. Moreover, oligonucleotide 
microarrays specific for 180 human and mouse 
miRNAs and Northern blotting methods were used to 
profile expression of MIRN21. In glioblastoma tissue  
its expression showed 5 to 100 fold increase compared 
to non-neoplastic brain sample and 5 to 30 fold 
increase in cell lines compared to normal. 
Oncogenesis 
Apoptosis: Loss-of-function approach was used to 
identify the biological significance of MIRN21 in 
glioblastoma cells. Sequence specific inhibitors (2’-O-
methyl-oligonucleotides) were used to knock-down 
MIRN21 transcript and apoptosis activity (caspase-3  
and caspase-7 enzymatic activities) was measured. 48 
hours post-transfection, caspase activity increased 3-
folds suggesting that MIRN21 acted as an anti-
apoptotic factor in glioblastoma cells through blocking 
expression of key apoptosis-enabling genes. 
Breast Cancer 
Disease 
RNAs from 76 breast cancer tumors and 14 cell lines 
were analyzed by using miRNA microarray and 
Northern blotting (10 normal samples were used for 
comparison and normalization). MIRN21 was up-
regulated and the results were confirmed by Northern 
blotting. 
Consistent with other studies, MIRN21 overexpression 
in breast tumors compared to matched normal breast 
tissues was verified by stem-loop RT real-time PCR 
and miRNA microarrays containing 157 mature human 
miRNAs. 
Oncogenesis 
Apoptosis: Inhibition of MIRN21 in breast cancer cell 
line MCF-7 by transfection of anti-mir-21 inhibitors 
(chemically modified oligonucleotides) showed growth 
inhibition. Treatment of transfected MCF-7 cell line 
with anticancer drug topotecan (TPT) caused cell 
growth inhibition by 40%. The results suggested 
suppression of MIRN21 gene could sensitize tumor 
cells to anticancer drugs. Inhibition of MIRN21 in a 
xenograft carcinoma mouse model verified tumor 
growth suppression. 
Transfection results of MCF-7 cells with a general 
caspase inhibitor suggested MIRN21 role in regulation 
of bcl-2 gene expression indirectly, possibly contrlling 




16 pancreatic adenocarcinomas and 10 adjacent benign 
tissues compared to 6 normal pancreas samples were 
analyzed for MIRN21 precursor expression and 
compared to mature MIRN21 by using real-time PCR 
assay. The results were consistent between precursor 
and mature MIRN21 showing overexpression. 
Neuroblastoma 
Disease 
Neuroblastoma cell line, SH-SY5Y, was treated with a 
tumor promoting agent (12-O-tetradecanoyl phorbol 
13-acetate (TPA)) to induce differentiation into a 
neuronal phenotype. Following stimulation, microarray 
analysis of stem-loop precursors was performed and 
MIRN21 showed 7-8 times higher expression 
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compared to other up-regulated miRNAs showing 2-4 
times relative increase. 
Lung cancer 
Disease 
Analysis of 104 pairs of primary lung cancers and non-
cancerous lung tissues by microRNA microarray 
showed differential expression of mature MIRN21 
among phenotypical and histological classifications. 
The results were confirmed by solution hybridization 
and RT-PCR. The results verified up-regulation of 
MIRN21 in lung cancer tissues compared to normals. 
Moreover, real time RT-PCR results for stem-loop 
precursor of MIRN21 showed at least 2-fold up-
regulation in 66% of 32 cases. 
Other cancers 
Disease 
In other miRNA microarray studies, MIRN21 was 
found to be overexpressed in papillary thyroid cancer, 
hepatocellular carcinoma, cholangiocarcinomas and 
uterine leiomyomas. A study suggested that MIRN21 
inhibition in a cervical adenocarcinoma cell line, HeLa, 
caused increase in cell growth. 
Prognosis 
MIRN21 (as well as 7 other miRNAs) expresion was 
correlated with adenocarcinoma patients¹ survival. 
Patients that have high expression of MIRN21 were 
found to have worse prognosis. Thus, in addition to 
potential role of MIRN21 in lung carcinogenesis 
through apoptosis pathway, it was suggested that 
expression profiles could be informative in 
adenocarcinoma patient survival. 
Cytogenetics 
Genomic amplification of chromosome band 17q23.2 
in neuroblastoma, breast cancer, colon cancer, lung
cancer is known. 
Oncogenesis 
Apoptosis: MIRN21 was found to be highly over-
expressed in malignant cholangiocytes. In 
cholangiocarcinoma cells it was shown that one of the 
targets of MIRN21 was PTEN encoding phosphatase 
that inhibited the survival and growth promoting 
activity of PI 3-kinase (phosphoinositole 3-kinase) 
signaling. 
In another report, inhibiton of MIRN21 showed 
increased sensitivity to gemcitabine. The results 
suggested that MIRN21 regulated gemcitabine-induced 
apoptosis by PTEN (phosphatase and tensin homolog) 
dependent activation of PI 3-kinase and AKT/mTOR 
signaling. These studies suggested anti-apoptotic rle 
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